Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA/ISOPP 2019 | Biosimilars in pharmacy practice: trastuzumab, rituximab and beyond

Rob Duncombe • 10 Oct 2019
BOPA/ISOPP 2019
Rituximab Trastuzumab

Biosimilars can bring many benefits; here, Rob Duncombe, of the Christie NHS Foundation Trust, Manchester, UK, discusses the biosimilars currently being used in cancer treatment, and the key role of pharmacists in their implementation and usage. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

More from Rob Duncombe

How may Brexit impact pharmacy?
0:50
How may Brexit impact pharmacy?
Rob Duncombe • 10 Oct 2019
Demand for oncology pharmacists in the clinic
1:43
Demand for oncology pharmacists in the clinic
Rob Duncombe • 10 Oct 2019
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe • 10 Oct 2019
Global oncology pharmacy collaboration: ISOPP and BOPA
1:03
Global oncology pharmacy collaboration: ISOPP and BOPA
Rob Duncombe • 10 Oct 2019

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals